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Background: A current debate concerning suspected superficial vein thrombosis (SVT) focuses on the need of performing
a compression ultrasound (CUS) exploration for confirming the diagnosis of SVT. This study was conducted to
determine the clinical relevance and optimal CUS exploration in patients with symptomatic SVT.
Methods: We analyzed the characteristics of SVT and concomitant deep vein thrombosis (DVT) in patients included in the
Prospective Observational Superficial Thrombophlebitis (POST) multicenter, observational prospective study. All
patients underwent complete bilateral lower limb CUS, exploring both the superficial and deep venous systems.
Results: A total of 844 patients with clinical symptoms of SVT were recruited, of which 99 isolated SVTs (21.4%) had
saphenofemoral/popliteal junction involvement, and 198 (23.5%) had a concomitant DVT, with 41.8% of them proximal
DVTs. In 83 patients (41.9%), DVT and SVT were not contiguous. Five of 639 patients (1%) had an isolated contralateral
DVT (ie, not bilateral). Age >75 years (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.6-3.4), inpatient status
(OR, 5.4; 95% CI, 3.4-8.7), a personal history of DVT or pulmonary embolism (OR, 1.8; 95% CI, 1.2-2.8), and SVT on
nonvaricose veins (OR, 3.3; 95% CI, 2.1-5.0) were significantly and independently associated with an increased risk of
concomitant DVT. Half of the patients exhibited none of these risk factors, and the prevalence of concomitant DVT
dropped to 11%.
Conclusions: In patients with symptomatic SVT, a CUS exploration screening the whole venous system of the affected
limb is useful because it provides information that has important consequences for the management of these patients.
(J Vasc Surg 2012;56:1032-8.)
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0Although superficial venous thrombosis (SVT) is a
frequent event, its diagnostic and therapeutic management
are currently under debate and vary widely from one coun-
try and physician to another; they are mostly empiric in
nature.1-6 Until recently, this disease had been poorly stud-
ied, and epidemiologic and therapeutic data were both
lacking. Indeed, no large epidemiologic study specifically
dedicated to SVT has been conducted, and previous ther-
apeutic trials have failed to demonstrate the superiority of
one treatment over another (placebo, surgery, nonsteroidal
anti-inflammatory agents, and different regimens of antico-
agulants).2,7,8
This situation is evolving; however, the large, random-
ized, double-blind Comparison of Arixtra in Lower Limb
Superficial Vein Thrombosis with Placebo (CALISTO)
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ind of symptomatic venous thromboembolic (VTE)
vent, including pulmonary embolism (PE), deep vein
hrombosis (DVT), SVT recurrence, and SVT extension,
mong patients with symptomatic, objectively confirmed
solated SVT (without concomitant DVT or PE) of5 cm
n length.9
From a diagnostic viewpoint, recent studies have evi-
enced that the risk of concomitant DVT could be ele-
ated, suggesting the need for a compression ultrasound
CUS) exploration in patients with symptoms suggestive of
VT, at least among high-risk patients.10-15 However, if
eeded, the way this exploration might be conducted has
ot been assessed.
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Volume 56, Number 4 Quéré et al 1033In this perspective, we analyzed data from the large,
prospective, multicenter, observational Prospective Obser-
vational Superficial Thrombophlebitis (POST) study.16
POST recruited patients with symptomatic SVT objectively
confirmed by a standardized bilateral whole leg CUS ex-
ploration. The main objective of the present work was to
determine the clinical relevance of CUS in patients with
suspected SVT by analyzing the characteristics of SVTs on
ultrasound imaging and concomitant DVT in patients with
a symptomatic SVT. A secondary objective was to deter-
mine clinical predictive factors for concomitant DVT to
identify high-risk patients.
METHODS
The POST study is a prospective, multicenter, observa-
tional study in France of inpatients and outpatients with
objectively confirmed symptomatic SVT of the lower limbs.
The study methods have been extensively described else-
where.16 It is available at http://ClinicalTrials.gov (regis-
tration number NCT00818688). In this article, we focus
on patients with isolated SVT and on patients with SVT
with concomitant DVT at inclusion. This substudy ex-
cluded patients exhibiting an SVT with concomitant PE
but without DVT.
Patients. The study enrolled patients with a symptom-
atic lower limb SVT who had been referred to vascular
medicine physicians who were members of the Société
Française de Médecine Vasculaire or of the Société Fran-
çaise de Phlébologie. To be eligible, patients had to be aged
18 years with a symptomatic, objectively confirmed,
lower limb SVT of 5 cm in length. Patients who had
undergone surgery 10 days, those with an SVT that
occurred 30 days after sclerotherapy, and those who
could not participate in the follow-up assessments were
excluded.
All patients underwent a complete bilateral lower limb
CUS study to confirm the diagnosis of SVT and to search
for an occult concomitant DVT. The following veins were
scanned transversally over their entire length: inferior vena
cava, iliac veins, femoral veins, popliteal veins, anterior and
posterior tibial veins, fibular veins, medial and lateral gas-
trocnemius veins, soleal veins, the saphenofemoral/popli-
teal junctions, the trunk of the great saphenous vein (GSV)
and small saphenous vein (SSV), and whenever thrombosis
was clinically suspected.
The diagnosis of SVT was confirmed by the presence of
a subcutaneous noncompressible hypoechoic area in the
course of an identified superficial vein 5 cm. Clot diame-
ter under compression was measured along with the dis-
tance from the saphenofemoral/popliteal junctions. We
considered that an involvement of a saphenous junction
was present if the clot was located3 cm from the junction.
An involvement of a contiguous perforating vein was sys-
tematically searched. Diagnosis of DVT was evidenced if
there was incompressibility of a deep vein or a lack of
spontaneous or reverse-flow intraluminal color filling after
augmentation maneuvers (ie, manual squeezing of the
calf). In case of clinical suspicion of PE, a ventilation- merfusion scan or a helical computed tomography scan was
btained.
Study protocol. At inclusion, the vascular medicine
hysician in charge of the patient collected all demographic
haracteristics, clinical data, and diagnostic test results. The
tudy was conducted in accordance with the declaration of
elsinki (Hong Kong amendment) and was approved by
he Ethics Committee of the Centre Hospitalier Universi-
aire de Saint-Étienne and the Commission Nationale de
’Informatique et des Libertés.16
Clinical risk factors for concomitant DVT. The
nfluence of the following potential risk factors for concom-
tant DVT was analyzed: age, sex, inpatient and outpatient
tatus, and anticoagulant treatment at inclusion. Transient
isk factors for concomitant DVT studied were hospitaliza-
ion or recent immobilization (within the last 20 days),
ecent travel (within the last 20 days), recent trauma, recent
urgery (10-60 days previous), plaster immobilization of
he lower limb, recent infectious disease, pregnancy, or
ecent childbirth. Chronic risk factors studied were a per-
onal history of DVT or PE, a family history of VTE, a
nown biologic thrombophilia at inclusion, autoimmune
isease, varicose veins, chronic reduced mobility, obesity
body mass index 30 kg/m2), oral contraception, con-
estive heart failure or respiratory insufficiency, coronary
eart disease, and active cancer, defined as newly diagnosed
ancer or receiving antineoplastic treatment of any type or
ancer in palliative care.
CUS risk factors for concomitant DVT. We studied
he influence of the following CUS variables on the risk of
oncomitant DVT:
● Variables previously reported in the literature as poten-
tial risk factors: involvement of the GSV trunk, of
perforating veins, distance from the saphenofemoral/
popliteal junctions (an involvement of the junction was
considered as present if the distance from the clot to
the junction was 3 cm), proximal or distal localiza-
tion of SVT (above-knee SVT of the GSV vs below-
knee SVT of the GSV and SVT of the SSV), and SVT
on nonvaricose veins.2,3
● Variables reflecting a prothrombotic state: multiple
SVTs.
● Variables reflecting a previous DVT: post-thrombotic
sequelae, defined as a composite of wall thickening and
the presence of an echogenic endoluminal clot.
Statistical analysis. Qualitative data are reported as
umbers and percentages and quantitative data as median
alues and interquartile ranges. Potential clinical risk factors
or concomitant DVT were estimated using univariate lo-
istic regressionmodels. Only variables with a prevalence of
3% in each group were tested. A multivariate logistic
egression was performed to estimate the adjusted odds
atio (OR) and corresponding 95% confidence interval (CI)
ssociated with each clinical risk factor for SVT and DVT vs
solated SVT. Independent clinical variables achieving a
alue of P  .15 in univariate analysis were included in the
ultivariate logistic model. Two-sided values of P  .05
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October 20121034 Quéré et alwere considered as statistically significant. Statistical analy-
ses were performed using SAS 9.1 software (SAS Institute,
Cary, NC).
RESULTS
Patient characteristics. Between March 2005 and
October 2006, 844 patients with a symptomatic lower limb
SVT were included by 79 private practices and 17 hospital-
based vascular medicine physicians distributed throughout
metropolitan France (Fig). Of these, 634 patients (75.1%)
presented with an isolated SVT, 198 (23.5%) with a con-
comitant DVT (with or without PE), and nine (1.1%) with
a concomitant symptomatic PE without DVT. In three
patients, the nature of the deep VTE event (DVT or PE)
was not reported in the case report form and is missing.
Characteristics of patients with isolated SVT and of patients
with SVT with concomitant DVT (with or without PE) are
presented in Table I.
Anatomic and ultrasound localization of SVT. The
SVTs were located as follows:
● Localization of SVT: For isolated SVTs, the following
veins were affected: the GSV in 401 patients (63.4%),
the SSV in 90 (14.2%), and another superficial vein in
231 (36.4%), and several veins in 84 patients (13.3%).
The respective patients with GSV, SSV, another vein,
and several veins’ involvement in the case of SVT with
concomitant DVT were 144 (72.7%), 52 (26.3%), 59
(29.8%), and 49 (24.7%).
● Side of SVT: 285 isolated SVTs (45.0%) affected the
right lower limb, 300 (47.4%) the left lower limb, and
48 (7.6%) were bilateral. The respective patients with
SVTs and concomitant DVT were 88 (44.4%), 91
(46.0%), and 19 (9.6%).
● Saphenofemoral/popliteal involvement of SVT: 185
patients (29.2%) had an involvement of a saphenous
junction (distance from the junction 3 cm): 99
Fig. Flow chart of the study.DVT,Deep vein thrombosi
VTE, venous thromboembolism.(21.4%) with an isolated SVT and 86 (50.6%) with fSVT and a concomitant DVT; 102 (19.6%) with GSV
thromboses had a saphenofemoral involvement and 89
(62.7%) with SSV thromboses had a saphenopopliteal
involvement (Table II).
Anatomic distribution of concomitant DVTs. Among
he 198 patients with a concomitant DVT, 82 (41.8%) had
proximal DVT and 24 (12.1%) also had a symptomatic
E. In the latter case, the DVT was more often a proximal
VT than in case of DVT without PE: 14 (58.3%) vs 68
39.5%), respectively (Table III). Nineteen patients
28.4%) with a bilateral SVT also had a concomitant DVT.
A total of 114 DVTs (58.2%) were distal, of which 51
44.7%) affected deep calf veins, 75 (37.9%) affected the
ight lower limb, 88 (44.4%) the left lower limb, and 35
17.7%) were bilateral. The DVT was not contiguous with
he SVT in 83 patients (41.9%), and 34 DVTs (17.2%)
ffected the contralateral leg: 29 bilateral and five unilateral
VTs, comprising two isolated asymptomatic distal DVTs,
ne symptomatic distal DVT, one locally asymptomatic
istal DVT with concomitant symptomatic PE, and one
symptomatic proximal DVT with concomitant symptom-
tic PE. Five patients with an SVT, representing1% of all
OST patients, had an isolated contralateral DVT (ie, not
ilateral). None of these DVTs was isolated proximal (ie,
ithout symptomatic PE).
Clinical risk factors for concomitant DVT.
nivariate analysis showed that age 75 years, inpatient
tatus, a personal history of DVT/PE, and SVT on non-
aricose veins were significantly more associated with SVT
ith concomitant DVT than with isolated SVT (Table IV).
hese results were confirmed in multivariate analysis.
At least one of the mentioned clinical risk factors was
resent in 468 of 816 patients (57.4%). The prevalence of
oncomitant DVT in this patient subgroup was 33% (155
f 468) comparedwith 11% in the absence of risk factor (39 of
48). The proportion of patients with at least two, three, and
pulmonary embolism; SVT, superficial vein thrombosis;s; PE,our risk factors and their associated proportion of concomi-
m
1
(
p
(
ber (%
monar
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Volume 56, Number 4 Quéré et al 1035tantDVTwere, respectively: 17.7% (143 of 808) and 52% (75
of 143) in case of at least two risk factors, 2.1% (17of 816) and
70.6% (12 of 17) in case of at least three risk factors,1% (4 of
806) and 75% (3 of 4) in case of four risk factors.
CUS risk factors for concomitant DVT. Compared
Table I. Baseline characteristics of study patients
Variablesa
Characteristics
Patients
Age, years
Median, IQR
75 years
Women
Interval between symptom onset and diagnosis
Median, days (IQR)
7 days
Anticoagulant treatment at inclusion
Transient risk factors for VTE
Inpatient or recent immobilization
Recent trauma
Recent surgery
Plaster immobilization
Recent travel
Recent infection
Pregnancy or postpartum
Chronic risk factors for VTE
Personal history of DVT/PE
Family history of VTE
Known thrombophilia
Active cancer
Heart failure or respiratory insufficiency
Coronary heart disease
Autoimmune disease
No varicose vein
Reduced mobility
Obesity
Oral contraception
DVT,Deep vein thrombosis; IQR, interquartile range; PE, pulmonary embo
aContinuous data are presented as median (IQR) and categoric data as num
Table II. Risk factors for concomitant deep vein thrombo
superficial venous thrombosis (SVT) by univariate analysis
Characteristics
SVT  DVT/PE
n  198
No. (%)
Above-knee SVT 78/176 (44.3)
GSV trunk 144/198 (72.7)
Length from SFJ
10 cm 59/135 (43.7)
3 cm 49/135 (36.3)
Length from SPJ
10 cm 43/52 (82.7)
3 cm 41/52 (78.8)
Perforating vein involvement 70/198 (35.3)
Multiple SVTs
Bilateral 19/198 (9.6)
2 49/198 (24.8)
Post-thrombotic sequelae 26/186 (14.0)
Varicose vein 113/171 (66.1)
CI, Confidence interval; GSV, great saphenous vein;OR, odds ratio; PE, pulwith other SVTs, those affecting the trunk of the GSV were eore likely to be associated with a DVT (OR, 1.5; 95% CI,
.1-2.2). Likewise, SVTs close to the deep venous system
close to the saphenofemoral/popliteal junctions, affecting
erforating veins) were at higher risk of concomitant DVT
Table II). Bilateral SVTs were not associated with an
SVT  DVT  PE Isolated SVT
198 (23.8) 634 (76.2)
70 (61-78) 61 (48-73)
71/198 (35.9) 131/634 (20.7)
126/198 (63.6) 412/634 (64.9)
7 (4-12) 5 (3-10)
64/153 (41.8) 232/623 (37.2)
67/197 (34.0) 173/626 (27.6)
55/198 (27.8) 49/632 (7.7)
3/198 (1.5) 41/634 (6.5)
11/198 (5.6) 25/634 (3.9)
1/198 (0.5) 2/632 (0.3)
8/198 (4.0) 59/634 (9.3)
12/198 (6.1) 18/633 (2.8)
1/197 (0.5) 36/634 (5.7)
56/192 (29.2) 120/617 (19.4)
48/189 (25.4) 206/629 (32.7)
14/194 (7.2) 34/630 (5.4)
26/192 (13.5) 24/630 (3.8)
17/196 (8.7) 33/625 (5.3)
6/195 (3.1) 35/628 (5.6)
11/196 (5.6) 8/628 (1.3)
63/197 (32.0) 87/634 (13.7)
29/195 (14.9) 34/629 (5.4)
57/197 (28.9) 183/632 (29.0)
8/196 (4.1) 32/628 (5.1)
VT, superficial venous thromboembolism;VTE, venous thromboembolism.
).
VT) according to the ultrasound characteristics of the
Isolated SVT
OR (95% CI) P
n  634
No. (%)
171/470 (36.4) 1.4 (1.0–2.0) .07
401/632 (63.4) 1.2 (1.1–1.3) .01
92/386 (23.8) 2.5 (1.6–3.8) .001
53/386 (13.7) 3.6 (2.3–5.6) .001
71/90 (78.9) 1.3 (0.5–3.1) .6
48/90 (53.3) 3.3 (1.5–7.2)) .003
40/631 (6.3) 8.1 (5.2–12.5) .001
48/633 (7.6) 1.3 (0.7–2.2) .2
84/632 (13.3) 2.1 (1.4–3.2) .001
47/627 (7.5) 2.0 (1.2–3.3) .001
514/597 (86.1) 0.3 (0.2–0.5) .001
y embolism; SFJ, saphenofemoral junction; SPJ, saphenopopliteal junction.lism; Ssis (Dxcess of risk of concomitant DVT or clot diameter under
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and DVT groups).
DISCUSSION
The main objective of the present work was to deter-
mine the clinical relevance of CUS imaging in patients with
symptomatic SVT. In this perspective, we described the
CUS characteristics of SVTs and their association with
concomitant DVTs at presentation.
First, our data suggest that performing aCUS exploration
in case of suspicion of SVT might be of interest because it is
likely to modify the therapeutic management in a significant
Table III. Description of deep vein thrombosis (DVT) ev
Variable
Total
No. (%)
DVT 198
Level of the DVT
Proximal 82/196a (41.8)
Distal 114/196a (58.2)
Deep calf 51/114 (44.7)
Muscular 63/114 (55.3)
Kind of DVT
DVT with PE 24/198 (12.1)
Proximal 14/24 (58.3)
Distal 10/24 (41.7)
DVT without PE 174/198 (87.9)
Proximal 68/172a (39.5)
Distal 104/172a (60.5)
PE, Pulmonary embolism.
aExact localization of DVT is missing in two patients.
Table IV. Univariate and multivariate analysis of clinical r
symptomatic superficial vein thrombosis (SVT)
Characteristics O
Age 75 years 2
Women 0
Interval between symptom onset and diagnosis 7 days 1
Transient risk factors for VTE
Inpatients or recent immobilization 4
Recent surgery 1
Recent travel 0
Chronic risk factors for VTE
Personal history of deep VTE 1
Family history of VTE 0
Known thrombophilia 1
Active cancer 4
Heart failure or respiratory insufficiency 1
Coronary heart disease 0
No varicose vein 3
Reduced mobility 3
Obesity 1
Oral contraception 0
CI, Confidence interval; OR, odds ratio; PE, pulmonary embolism; VTE, ve
Variables achieving a P  .15 were introduced in the multivariate analysis mproportion of patients: 25% of patients had a concomitant rVT and 21% of isolated SVTs displayed an involvement of a
aphenous junction. The concomitant DVT was distal in 60%
f cases, themanagement of which is debated; in 40% of cases,
he DVT was proximal and indisputably necessitated the full
herapeutic dose of anticoagulants.17,18
The thrombus generally conceded to extend from the
uperficial to the deep venous system by contiguity,
hrough the perforating veins and the saphenous junc-
ions.15 This is in line with the finding that in case of SVT,
ost concomitant DVTs are distal because the perforating
eins network is more developed at the calf level than at the
high.11,19,20 This could plead in favor of a limited explo-
at presentation
Contiguous Noncontiguous
No. (%) No. (%)
115/198 (58.1) 83/198 (41.9)
53/113a (46.9) 29/83 (34.9)
60/113a (53.1) 54/83 (65.1)
22/60 (36.7) 29/54 (53.7)
38/60 (63.3) 25/54 (46.3)
8/115 (7.0) 16/83 (19.3)
6/8 (75.0) 8/16 (50.0)
2/8 (25.0) 8/16 (50.0)
107/115 (93.0) 67/83 (80.7)
47/107a (43.9) 21/67 (31.3)
58/107a (54.2) 46/67 (68.7)
ctors for concomitant deep vein thrombosis (DVT) with
SVT  DVT  PE vs SVT
Univariate analysis Multivariate analysis
5% CI) P OR (95% CI) P
.5–3.0) .0001 2.3 (1.6–3.4) .0001
.7–1.3) .05 . . . . . .
.9–1.7) .05 . . . . . .
.0–7.0) .0001 5.4 (3.4–8.7) .001
.7–3.0) .05 . . . . . .
.2–0.9) .02 0.7 (0.3–1.5) .05
.2–2.5) .005 1.8 (1.2–2.8) .005
.5–1.0) .06 0.8 (0.5–1.2) .05
.7–2.6) .05 . . . . . .
.2–7.1) .0001 1.7 (0.9–3.4) .05
.9–3.1) .08 1.0 (0.5–2.1) .05
.2–1.3) .05 . . . . . .
.0–4.3) .001 3.3 (2.1–5.0) .0001
.8–5.2) .0001 1.3 (0.7–2.4) .05
.7–1.4) .05 . . . . . .
.4–1.6) .05 . . . . . .
thromboembolism.entsisk fa
R (9
.2 (1
.9 (0
.2 (0
.6 (3
.4 (0
.4 (0
.7 (1
.7 (0
.4 (0
.0 (2
.7 (0
.5 (0
.0 (2
.1 (1
.0 (0
.8 (0ation of the deep venous system. In the POST study,
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Volume 56, Number 4 Quéré et al 1037analysis of the anatomic characteristics of SVTs revealed
that even if an involvement of perforating veins and of the
saphenofemoral/popliteal junctions were strongly associ-
ated with an increased risk of concomitant DVT, almost
half of DVTs were not contiguous with the SVT. This
suggests that the CUS exploration should screen the entire
deep venous system and should not be limited to the
adjacent deep veins.
Finally, 34 DVTs (17%) affected the contralateral lower
limb. The DVT in 29 (85%) was also present in the leg
affected by the SVT (ie, bilateral DVT). Less than 1% of the
patients had an isolated contralateral DVT and none had an
isolated proximal DVT (ie, without symptomatic PE). It
might not be indispensable to systematically perform a
bilateral exploration of the entire leg to search for a poten-
tial concomitant DVT; our data indicate that a unilateral
screening is sufficient.
Because SVT is mainly a primary care disease, access to
CUS exploration may not be easy, and a number of physi-
cians may be reluctant to systematically perform such an
examination. In this context, determination of predictive
factors for concomitant DVT is of interest because it may
help in selecting patients requiring an ultrasound examina-
tion or identifying high-risk patients who require an urgent
exploration or anticoagulation while waiting for diagnostic
tests. As previously described, we confirmed the influence
of age, hospitalization, SVT on a nonvaricose vein, and a
personal history of DVT/PE, on the risk of concomitant
DVT.10,11,21-24 Thus, almost half of the patients exhibited
none of the aforementioned risk factors, and the prevalence
of concomitant DVT in this subgroup dropped to 11%.
However, the prevalence of DVT was tripled in the pres-
ence of at least one risk factor.
Our study presents some limitations. We are aware that
SVT is usually perceived as a primary care disease, and
extrapolation of our rate of DVT at presentation may not
be relevant in a primary care setting. We cannot exclude
that general practitioners limited the patients they referred
to those at higher risk of DVT. However, we believe that
this risk, although real, is limited: (1) in France, access to
CUS examination is easy, and general practitioners are
accustomed to extensively referring to secondary care phy-
sicians, who represent 50% of the medical population; (2)
we restricted our SVT population to only clinically relevant
SVT (symptomatic and length 5 cm), yet at higher
risk.8,25 Finally, because of the exclusively observational
design of our study, we were not able to provide data on the
influence of biologic thrombophilia on the risk of concom-
itant SVT, as previously described.14
Among the strengths of our study, we point out that
unlike most previous epidemiologic studies on SVT, we
included a large number of patients recruited consecutively,
prospectively, and in a multicenter design.15 All SVTs were
confirmed on CUS exploration according to a rigorous
protocol. Only the OPTimisation de l’Interrogatoire pour
la Maladie thromboEmbolique Veineuse (OPTIMEV)
study had a similar design.10 We believe that those two
studies are complementary: In the OPTIMEV study, whichimed to analyze the risk factors and outcomes of the
ifferent presentation of VTE disease, there was no medi-
al/ultrasound-based exclusion criterion. The OPTIMEV
esults apply to symptomatic SVT of any kind routinely
anaged in secondary care practice. The POST survey,
owever, was specifically dedicated to SVT, and character-
stics of the SVT were similar to that of the CALISTO trial
symptomatic SVT of 5 cm in length).
We also have information on the symptomatic charac-
er of contralateral DVT and on the distance of the clot
rom the saphenopopliteal/femoral junctions. Although
ates of concomitant DVT were different between POST
nd OPTIMEV (23.5% vs 28.8%), this probably only re-
ects the difference between the populations studied, with
igher rates of inpatients and patients with active cancer in
PTIMEV. Furthermore, most independent predictive
actors for concomitant DVT, which are not likely to be
reatly influenced by population characteristics, were
ound in both studies: elevated age, inpatient status, and
VT on nonvaricose veins. The 3.9% prevalence of symp-
omatic PE in our population is in the range of the 0% to
0% prevalence previously reported.15 The same is true for
he distribution of the localization of SVTs and the propor-
ions of noncontiguous and bilateral DVTs.3,10,11,19,20
e therefore believe that our recruitment of SVT is repre-
entative of SVT seen in routine practice.
ONCLUSIONS
In secondary care patients, given the high prevalence of
VTs, almost half of which are proximal DVTs, a CUS
xploration should be performed in patients with symp-
omatic SVT because it could provide important informa-
ion to guide management. The exploration should not be
imited to the superficial venous system but should be
xtended to the entire deep venous system of the affected
eg. The cost-effectiveness of such a strategy needs to be
valuated, however. Age 75 years, a personal history of
VT/PE, SVT on nonvaricose veins, or recent immobili-
ation significantly and independently increase the risk of
aving a concomitant DVT.
We acknowledge Carey Suehs for English editing and
ohra Akkal for coordinating the study, which was per-
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édecine Vasculaire and the Société Française de Phlébo-
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